Literature DB >> 15371672

Surgical site infection in living-donor liver transplant recipients: a prospective study.

Yoshitsugu Iinuma1, Kazuyoshi Senda, Naoko Fujihara, Takashi Saito, Shunji Takakura, Toyoichiro Kudo, Tetsuya Kiuchi, Koichi Tanaka, Satoshi Ichiyama.   

Abstract

BACKGROUND: Infection is a constant threat for the living-donor liver transplantation (LDLT) recipients, although little information is available on the occurrence of infection in such patients.
METHODS: One hundred and thirteen consecutive LDLT recipients were prospectively followed for the presence of surgical site infections (SSIs) defined by CDC from April 2001 to March 2002. Risk factors for SSIs were evaluated by univariate and multivariate analysis.
RESULTS: Of the 113 LDLT recipients, 42 (37%) developed 57 episodes of SSIs (21 intraabdominal abscess, 20 peritonitis, 8 cholangitis, and 9 wound). Of the 57 episodes, 29 (51%) had secondary bacteremia in 19 patients. Causative pathogens, including 17 episodes of polymicrobial infections, were 37 gram-positive cocci (17 Staphylococcus aureus, 16 Enterococcus spp., and 4 others), 40 gram-negative rods (25 Enterobacteriaceae, 13 Pseudomonas aeruginosa, and 4 others), and 2 Candida albicans. Univariate analysis revealed that ABO incompatibility and repeat surgery were associated with the development of SSIs. Also, univariate analysis revealed that adult recipients, ABO incompatibility, total operation duration, repeat surgery, and NNIS risk index were associated with secondary bacteremia. Multivariate analysis revealed that ABO incompatibility (OR: 14.0; 95% CI, 2.52-77.2) and repeat surgery (OR: 9.29; 95% CI, 2.00-43.1) were independently associated with secondary bacteremia. Eleven of the 42 cases (26%) who developed SSIs died. Of these 11 cases, 5 (45%) developed secondary bacteremia within 30 days before death.
CONCLUSION: SSIs occurred in 37% of LDLT recipients. ABO incompatibility and repeat surgery increased the risk of developing SSIs with secondary bacteremia, which correlated with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371672     DOI: 10.1097/01.tp.0000130178.17216.28

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Spectrum of early-onset and late-onset bacteremias after liver transplantation: implications for management.

Authors:  Sang-Oh Lee; Seung H Kang; Rima C Abdel-Massih; Robert A Brown; Raymund R Razonable
Journal:  Liver Transpl       Date:  2011-06       Impact factor: 5.799

Review 2.  Antibiotic prophylaxis for surgical site infection in people undergoing liver transplantation.

Authors:  Ricardo A M B Almeida; Claudia N Hasimoto; Anna Kim; Erica N Hasimoto; Regina El Dib
Journal:  Cochrane Database Syst Rev       Date:  2015-12-05

Review 3.  Surgical site infection prevention and management in immunocompromised patients: a systematic review of the literature.

Authors:  Federico Coccolini; Mario Improta; Enrico Cicuttin; Fausto Catena; Massimo Sartelli; Raffaele Bova; Nicola De' Angelis; Stefano Gitto; Dario Tartaglia; Camilla Cremonini; Carlos Ordonez; Gian Luca Baiocchi; Massimo Chiarugi
Journal:  World J Emerg Surg       Date:  2021-06-10       Impact factor: 5.469

4.  Changes in Surgical Site Infections after Living Donor Liver Transplantation.

Authors:  Masaki Yamamoto; Shunji Takakura; Yoshitsugu Iinuma; Go Hotta; Yasufumi Matsumura; Aki Matsushima; Miki Nagao; Kohei Ogawa; Yasuhiro Fujimoto; Akira Mori; Yasuhiro Ogura; Toshimi Kaido; Shinji Uemoto; Satoshi Ichiyama
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

5.  Rates and causative pathogens of surgical site infections attributed to liver transplant procedures and other hepatic, biliary, or pancreatic procedures, 2015-2018.

Authors:  Nora Chea; Mathew R P Sapiano; Liang Zhou; Lauren Epstein; Alice Guh; Jonathan R Edwards; Katherine Allen-Bridson; Victoria Russo; Jennifer Watkins; Stephanie M Pouch; Shelley S Magill
Journal:  Transpl Infect Dis       Date:  2021-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.